Vischer in the the sale of Mestex AG to Grünenthal
- Deal & transactions
- 21 April 2021
- 217
- 2 minutes read
Vischer advised the sellers of Mestex AG on all legal issues related to the sale of their shares and stock options to the pharmaceutical company Grünenthal, a global operator in pain management and related diseases.
With the acquisition, Grünenthal aims to grow in the global market for osteoarthritis drugs and further strengthen its pain treatment-focused pipeline.
Vischer acted with a team led by Christian Wyss (Partner, Corporate/M&A) and Nadia Tarolli (Partner, Tax) with Luzius Zumstein (Associate, Corporate/M&A), Moritz Jäggy (Associate, Corporate/M&A), Pauline Pfirter (Associate, Corporate/M&A), and Adrian Briner (Associate, Tax).
In all matters of German law, Vischer was supported by Orrick Herrington & Sutcliffe led by Jörg Ritter and Christine Kaniak.
Mestex is a the Swiss biotech company developing, among other things, the novel compound MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The promising drug candidate MTX-071 is about to enter phase III clinical trials and could provide an innovative treatment option for millions of patients suffering from pain associated with knee osteoarthritis.
